Novartis
NEWS
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 3, 2020.
In a statement, the FDA said “objectionable conditions were found and documented” but did not meet the threshold for regulatory action against the Swiss pharma giant.
The following is a roundup of some of this week’s non-coronavirus biopharma news.
Novartis’ Isturisa (osilodrostat) was approved for adults with Cushing’s disease who either can’t have pituitary gland surgery or who have had the surgery but still have the disease.
The two companies forged a collaboration to discover and design novel small molecule therapeutics, such as protein degraders, across various therapeutic areas
The U.S. Department of Justice charged New Jersey-based Sandoz with four counts of conspiring to rig bids and fix prices for generic drugs.
The ASRS issued a note to its members about concerns regarding reports of vasculitis, an inflammation of the blood vessels and other complications that can lead to the loss of vision, as a potential side effect of treatment with Beovu.
The BioSpace Ideal Employer Report examined aspects regarding the importance of culture within life sciences organizations.
A number of new medications stand a shot at early regulatory approval thanks to the U.S. Food and Drug Administration’s priority review program.
JOBS
IN THE PRESS